Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. 19, 2025 /PRNewswire/ -- USA News Group News Commentary – The recent FDA approval in November of the first bispecific antibody combination for second-line blood cancer treatment marks the departure from traditional chemotherapy that oncologists have been anticipating for decades[1]. Engineered cell therapies and bispecific antibodies are now achieving response rates exceeding 90% in patients with relapsed and refractory hematologic malig

WHITMORE LAKE, Mich.--(BUSINESS WIRE)--Trace Medical, the national leader in advanced respiratory rentals and biomedical services has announced an equity investment in LiViliti Health Products Inc., an innovator of CPAP and respiratory accessories, based in Sarasota, Florida. Greg Apostolou, Chief Executive Officer of Trace Medical, stated “LiViliti and Trace are a natural fit, leveraging LiViliti’s suite of health cleaning products and core expertise with Trace Medical’s infrastructure and mark

Avicanna’s evidence-based pathway for cannabinoid-based medicine aligns with the executive order. Avicanna’s 2025 advances across R&D, clinical development, and medical affairs. TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products applauds President Trump’s executive order directing th

None\n This year felt like a million years packed into one, with so many significant and industry-changing moments occurring one after another. That fast-paced dynamic made it extremely challenging to choose my top story picks for 2025. The Fierce Biotech team rose to the occasion all year, producing an exceptional body of work, and I found myself with nearly 30 stories I was considering for this list. That being said, I’ve trimmed down the list to include four all-star stories

MSD declines to exercise option for EVX-B2 developmentEvaxion is now able to out-license EVX-B2 to another partnerEvaxion maintains its strong belief in EVX-B2, which has shown to be protective against Gonorrhea in preclinical studiesThere is no impact on Evaxion’s cash runway which extends to the second half of 2027 COPENHAGEN, Denmark, December 19, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has be

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including a growing alliance to curtail foodborne illnesses, and resources to help people quit nicotine and tobacco for good. NEW YORK, Dec. 19, 2025 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of som

Ahmedabad : Zydus Lifesciences Ltd on Friday said it has signed an exclusive agreement with US-based Myriad Genetics to introduce a range of cancer-risk assessment and prognostic diagnostic tests in India, aimed at supporting personalised and evidence-based cancer care. Under the agreement, Zydus will market and promote Myriad Genetics’ diagnostic platforms, including the MyRisk® Hereditary Cancer Test, MyChoice® HRD Plus test for ovarian cancer, and the Prolaris® prostate cancer prognostic test

BioMarin plans to dish out $4.8 billion to acquire Amicus Therapeutics and its two approved rare disease medicines, the California biotech said Friday. By gaining access to Amicus’ meds for Pompe and Fabry diseases, CEO Alexander Hardy is forging a key part of the future for BioMarin as part of a multiyear turnaround. The drugmaker has conducted layoffs , reorganizations and pipeline culls over the past few years to adjust the ship. “When I came to BioMarin two years ago, I came because I saw th

Sens. Bernie Sanders (I-VT) and Markwayne Mullin (R-OK) are not seeing eye to eye on why the Senate failed to pass legislation reauthorizing the FDA’s rare pediatric priority review voucher program. Mullin took to the Senate floor on Wednesday to urge lawmakers to renew the program, with support from Sens. Bill Cassidy (R-LA) and Maggie Hassan (D-NH). The transferable vouchers were created in 2012 to incentivize new drugs to treat rare pediatric illnesses, including rare cancers and genetic dise

Plus, news on: EpimAb, Boehringer and Nxera, Syneron, Amphix Altimmune goes to Phase 3 in MASH: The drug developer’s Phase 2 trial of pemvidutide, a GLP-1/glucagon agonist, failed in June. But based on a longer-term readout from that study, Altimmune is taking it to Phase 3 . In the new cut of data, the high dose of the drug appeared to help on several measures of liver health. Altimmune said it had held a “productive” meeting with the FDA about the data and was aligned with the regulator on pla